Volume 1.27 | Jul 23

Prostate Cell News 1.27, July 23, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


UT Southwestern Researchers Block Key Pathway in End-Stage Prostate Cancer Tumor Progression 
Researchers have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor’s growth. [Press release from University of Texas Southwestern Medical Center discussing online prepublication in Endocrinology]

Watch Procedure Now  
Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


BMD Testing Underused in ADT Recipients
Bone mineral density (BMD) testing and bisphosphonate use are significantly underused in men receiving androgen deprivation therapy (ADT) for prostate cancer, a new study suggests. [Renal & Urology News on study presented at the Canadian Urological Association’s Annual Meeting]

Salvage Cryotherapy an Option for Radiation Treatment Failures
New findings from a Canadian study support the use of salvage cryotherapy for prostate cancer patients who experience disease recurrence after radiation treatment. [Renal & Urology News on study presented at the Canadian Urological Association’s Annual Meeting]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Castration Resistance in Human Prostate Cancer is Conferred by a Frequently Occurring Androgen Receptor Splice Variant
Here, investigators have identified a novel human androgen receptor splice variant in which exons 5, 6, and 7 are deleted and demonstrated that this variant can contribute to cancer progression in human prostate cancer xenograft models in mice following castration. [J Clin Invest]

3[Beta]-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate Cancer
The findings demonstrate that dehydroepiandrosterone and [delta]5-androstenediolmust be metabolized by 3[beta]-hydroxysteroid dehydrogenase to activate androgen receptor in these models of castration-resistant prostate cancer. [Endocrinology]

Proteomic Profiling of Potential Molecular Targets of Methyl-Selenium Compounds in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model
The present work applied iTRAQ proteomic approach to profile protein changes of the TRAMP prostate and characterized their modulation by methylselenic acid and Se-methylselenocysteine to identify their potential molecular targets. [Cancer Prev Res]

Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines
In this study, researchers investigated androgen receptor (AR) binding and AR-dependent transcription in two related castrate-resistant cell lines derived from androgen-dependent CWR22 relapsed tumors: CWR22Rv1 and CWR-R1. [Endocr Relat Cancer]

P53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase
Based on the results, PIM1 will have its most profound effects on tumorigenesis in situations where the senescence response is inactivated. [Mol Canc Res]

Cryptotanshinone Sensitizes DU145 Prostate Cancer Cells to Fas(APO1/CD95)-Mediated Apoptosis Through Bcl-2 and MAPK Regulation
In the present study, researchers demonstrated that the apoptosis inhibitory protein, Bcl-2, was highly expressed in response to Fas in DU145 prostate cancer cells, thereby conferring resistance to apoptosis. [Cancer Lett]

Knockdown of Akt isoforms by RNA Silencing Suppresses the Growth of Human Prostate Cancer Cells In Vitro and In Vivo
Here, researchers investigated the expression and function of Akt isoforms in human prostatic carcinoma cells. [Biochem Biophys Res Commun]


Diagnosis of Prostate Cancer by Detection of Minichromosome Maintenance 5 Protein in Urine Sediments
In this study, researchers investigated minichromosome maintenance-5 as a urinary biomarker for prostate cancer detection. [Br J Cancer]

Open-Label, Phase I Dose-Escalation Study of Sodium Selenate, a Novel Activator of PP2A, in Patients with Castration-Resistant Prostate Cancer
Sodium selenate is well tolerated at a dose of 60mg per day with modest single-agent efficacy similar to other anti-angiogenic agents. [Br J Cancer]

Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
Researchers determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy. [J Urol


Safeway Prostate Cancer Campaign Nets $11.6 Million for Research
During what has become a familiar summer tradition that reaches millions of Safeway customers weekly, the company raised more than $11.6 million for prostate cancer research. [Press release from Safeway Inc.]

MediGene Sells Full European Rights for Eligard® to Astellas for EUR 25 Million and Ongoing Royalties
MediGene AG announces the sale of full European marketing and distribution rights to Eligard® to Astellas Pharma Europe Ltd., previously MediGene’s European marketing partner for Eligard®. [MediGene AG Press Release]

CytRx Announces Substantial Progress with Its Bafetinib Clinical Trials Program
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. [Press release from CytRx Corporation]


USC to Lead Prostate Cancer Study
Researchers received a $12 million National Cancer Institute grant to lead an international project aimed at identifying new biological pathways critical to the development and potential treatment of prostate cancer. [USC Norris Comprehensive Cancer Center ]

“Game Over” for British Science?
The Royal Society and the British Academy strongly warned the British government that looming cuts to science funding could be “irreversibly catastrophic for the future of U.K. science and economic growth” if they go too far. [The Royal Society and the British Academy, United Kingdom]

House Panel Approves 3.2% Raise for NIH in 2011
A House of Representatives spending panel yesterday approved a $1 billion increase, to $32 billion, in the 2011 budget for the National Institutes of Health (NIH). [National Institutes of Health, United States]

2011 NIH Directors New Innovator Award Program (DP2) (RFA-RM-10-009) [National Institutes of Health, United States]

Prospective Grant of Exclusive License: The Development of Human Therapeutics for the Treatment of Cancer [National Institutes of Health, United States]

Pre-Application Meeting for Request for Applications (RFA-CA-10-016) for the Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers (NOT-CA-10-031) [National Institutes of Health, United States]

Notice of Intent to Publish a Request for Applications for Tumor Microenvironment Network (TMEN) (NOT-CA-10-032) [National Institutes of Health, United States]

NIMH Announces Availability of Funds for Competitive Revision Applications for a Repository Supporting Stem Cell Research Relevant to Mental Disorders (U24) (NOT-MH-10-024) [National Institute of Mental Health, United States]

NASA SBIR/STTR 2010 Phase I Solicitation [Small Business Innovation Research, United States]

EVENTS (Listed by Date)

The Tissue and Cell Engineering Society 2010 Meeting
July 28-30, 2010
Manchester, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

9th Mount Desert Island Stem Cell Symposium
August 6-7, 2010
Salsbury Cove, United States

NEW Australian-Canadian Prostate Cancer Research Alliance Symposium
August 6-8, 2010
Gold Coast, Australia

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

NEW Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
California, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

NEW Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

NEW Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us